| DESCRIPTION | - ANGAL et al., Molecular Immunology, (19930000), vol. 30, page 105 |
| DESCRIPTION | - BENNET et al., Arch. Intern. Med, (20080000), vol. 168, pages 598 - 608 |
| DESCRIPTION | - GOODSON, Medical Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138 |
| DESCRIPTION | - IGNATESCU et al., Thromb. Haemost, (19980000), vol. 80, pages 231 - 232 |
| DESCRIPTION | - LAMON-FAVA et al., J. Lipid Res, (20110000), vol. 52, pages 1181 - 1187 |
| DESCRIPTION | - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533 |
| DESCRIPTION | - LIPPIGUIDI, Q. J. Med, (20000000), vol. 93, pages 75 - 84 |
| DESCRIPTION | - MARCOVINAKOSCHINSKY, Am. J. Cardiol, (19980000), vol. 82, pages 57U - 66U |
| DESCRIPTION | - NEIL et al., BMJ, (20000000), vol. 321, page 148 |
| DESCRIPTION | - PARHOFER, Curr. Pharm Des, (20110000), vol. 17, pages 871 - 876 |
| DESCRIPTION | - POWELL et al., "Compendium of excipients for parenteral formulations", J Pharm Sci Technol, (19980000), vol. 52, pages 238 - 311, XP009119027 |
| DESCRIPTION | - SEFTON, CRC Crit. Ref. Biomed. Eng., (19870000), vol. 14, page 201 |
| DESCRIPTION | - SIMON BROOME REGISTER GROUP, BMJ, (19910000), vol. 303, pages 893 - 896 |
| DESCRIPTION | - TAYLOR et al., Nucl. Acids Res, (19920000), vol. 20, pages 6287 - 6295 |
| DESCRIPTION | - "The Emerging Risk Factors Collaboration", J. Am. Med. Assoc, (20090000), vol. 302, pages 412 - 423 |
| DESCRIPTION | - WARNICK et al., J. Lipid Res, (19780000), vol. 19, pages 65 - 76 |
| DESCRIPTION | - WU et al., J. Biol. Chem., (19870000), vol. 262, pages 4429 - 4432 |
| OPPOSITION | - Anonymous, "Aber Lp(a) ist zu hoch, was kann man da tun?", Aktuelle Medizin, pages 22 - 22, Aktuelle Medizin, URL: https://link.springer.com/content/pdf/10.1007/BF03368423.pdf, XP093168119 |
| OPPOSITION | - D36 - Editorial and Journal Policies PNAS |
| OPPOSITION | - D42 - Declaration Dr Meador d.d. 7-02-2025 |
| OPPOSITION | - D45 - Statement of Claim EP’857 d.d. 26 February 2025 |
| OPPOSITION | - D46 - UPC decision EP,712 d.d. 13 May 2025 |
| OPPOSITION | - D51 - Clinical Trial Summary Document, trials on use of a lipid modifying therapy for use in treating ASCVD (2005-2012) |
| OPPOSITION | - D52 - Clinical Trial Summary Document, trials of anti-PCSK9 antibodies in lipid based diseases |
| OPPOSITION | - D7a - Dr Hegele curriculum vitae |
| OPPOSITION | - D7 - Declaration Dr Hegele d.d. 23-06-2025 |
| OPPOSITION | - Dahlén Gösta, "The Pre-beta, lipoprotein phenomenon in relation to serum cholesterol and triglyceride levels, the Lp(a) lipoprotein and coronary heart disease", ACTA MEDICA SCANDINAVICA. SUPPLEMENTUM., STOCKHOLM., SE, SE , (19740101), vol. 570, ISSN 0365-463X, pages 1 - 45, XP093293063 |
| OPPOSITION | - Kapitall, "These Companies Are Racing To Develop The Next Big Cholesterol Drug", Business Insider, pages 1 - 2, Business Insider, URL: https://www.businessinsider.com/hearty-profits-companies-racing-to-develop-the-next-big-cholesterol-drug-2011-8?international=true&r=US&IR=T, XP093292279 |
| OPPOSITION | - Patentee’s submission in the opposition against EP 3636712 d.d. 18 June 2024 |
| OPPOSITION | - Sp Tam, Zhang X, Koschinsky Ml, "Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2", JOURNAL OF LIPID RESEARCH, American Society for Biochemistry and Molecular Biology, Inc., US, US , (19960301), vol. 37, ISSN 0022-2275, pages 518 - 533, XP055390454 |
| OPPOSITION | - Swergold Gary, Stephanie Biedermann, Rumiana Renard, Doug Nadler, Richard Wu, Eleanor A. Lisbon, Maria J. Gutierrez, Scott Mellis, "REGN727/SAR236553, a Fully-Human Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Monoclonal Antibody: Effects on Safety and Lipid and Lipoprotein Profiles When Administered Subcutaneously", American College of Cardiology annual scientific session & expo 2011; April 3-5, 2011, American College of Cardiology, (20110403), pages 1 - 1, XP093262425 |
| OPPOSITION | - Ridker Paul, "A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction", JAMA, Clyancourt Corporation, Chicago, IL, Chicago, IL, (19931110), vol. 270, no. 18, doi:10.1001/jama.1993.03510180065035, ISSN 0098-7484, pages 2195 - 2199, XP009561818 |
| OPPOSITION | - David Sullivan, Anders G. Olsson, Rob Scott, Jae B. Kim, Allen Xue, Val Gebski, Scott M. Wasserman, Evan A. Stein, "Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients", JAMA, (20121219), vol. 308, no. 23, doi:10.1001/jama.2012.25790, ISSN 00987484, page 2497, XP055136453 |
| OPPOSITION | - Danik J.S., et al, "Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women", JAMA, Clyancourt Corporation, Chicago, IL, Chicago, IL, (20060920), vol. 296, no. 11, doi:10.1001/jama.296.11.1363, ISSN 0098-7484, pages 1363 - 1370, XP002609986 |
| OPPOSITION | - Gibbs John P., Doshi Sameer, Kuchimanchi Mita, Grover Anita, Emery Maurice G., Dodds Michael G., Gibbs Megan A., Somaratne Ransi, Wasserman Scott M., Blom Dirk, "Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)", The Journal of clinical pharmacology, LIPPINCOTT CO, HAGERSTOWN, MD, US, US , (20170501), vol. 57, no. 5, doi:10.1002/jcph.840, ISSN 0091-2700, pages 616 - 626, XP093067035 |
| OPPOSITION | - Davignon J; Dubuc G; Seidah N G, "The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis", Current Atherosclerosis Reports, Springer US, New York, New York, (20100901), vol. 12, no. 5, doi:10.1007/s11883-010-0123-6, ISSN 1523-3804, pages 308 - 315, XP009163743 |
| OPPOSITION | - Havekes, L. ; Vermeer, B.J. ; Brugman, T. ; Emeis, J., "Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts", FEBS Letters, ELSEVIER, AMSTERDAM., NL, NL , (19810928), vol. 132, no. 2, doi:10.1016/0014-5793(81)81153-2, ISSN 0014-5793, pages 169 - 173, XP025653591 |
| OPPOSITION | - Marz, W. ; Beckmann, A. ; Scharnagl, H. ; Siekmeier, R. ; Mondorf, U. ; Held, I. ; Schneider, W. ; Preissner, K.T. ; Curtiss, L.K. ; Grosz, W. ; Huttinger, M., "Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/@a"2-macroglobulin receptor", FEBS Letters, ELSEVIER, AMSTERDAM., NL, NL , (19930705), vol. 325, no. 3, doi:10.1016/0014-5793(93)81087-G, ISSN 0014-5793, pages 271 - 275, XP025614678 |
| OPPOSITION | - Christie Ballantyne, "CHALLENGES IN LIPOPROTEIN (a) MEASUREMENT", Clinical Lipidology. A Companion to Braunwald's Heart Disease, Elsevier , (20090101), pages 136 - 143, doi:10.1016/B978-141605469-6.50015-9, ISBN 978-1-4160-5469-6, XP055743471 |
| OPPOSITION | - Anuurad Erdembileg, Boffa Michael, Koschinsky Marlys, Berglund Lars, "Lipoprotein(a): A Unique Risk Factor for Cardiovascular Disease", CLINICS IN LABORATORY MEDICINE., Elsevier, US, US , (20061201), vol. 26, no. 4, doi:10.1016/j.cll.2006.07.002, ISSN 0272-2712, pages 751 - 772, XP009557782 |
| OPPOSITION | - Suet N. Chen, Ballantyne Christie M., Gotto Antonio M., Tan Yanli, Willerson James T., Marian Ali J., "A Common PCSK9Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis /NIH Author Manuscript/", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20050501), vol. 45, no. 10, doi:10.1016/j.jacc.2005.01.051, ISSN 0735-1097, pages 1611 - 1619, XP055740331 |
| OPPOSITION | - James M. McKenney; Michael J. Koren; Dean J. Kereiakes; Corinne Hanotin; Anne-Catherine Ferrand; Evan A. Stein;, "Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20120313), vol. 59, no. 25, doi:10.1016/j.jacc.2012.03.007, ISSN 0735-1097, pages 2344 - 2353, XP028490351 |
| OPPOSITION | - Clapton S. Dias, Adam J. Shaywitz, Scott M. Wasserman, Brian P. Smith, Bing Gao, Dina S. Stolman, Caroline P. Crispino, Karen V. Smirnakis, Maurice G. Emery, Alexander Colbert, John P. Gibbs, Marc W. Retter, Blaire P. Cooke, Stephen T. Uy, Mark Matson, Evan A. Stein, "Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels", Journal of the American College of Cardiology, Elsevier, (20121101), vol. 60, no. 19, doi:10.1016/j.jacc.2012.08.986, ISSN 07351097, pages 1888 - 1898, XP055079133 |
| OPPOSITION | - Alonso Rodrigo; Andres Eduardo; Mata Nelva; Fuentes-Jiménez Francisco; Badimón Lina; López-Miranda José; Padró Teresa; Muñiz Ovidio; Díaz-Díaz Jose Luis; Mauri Marta; Ordovás Jose María; Mata Pedro , "Lipoprotein(a) Levels in Familial Hypercholesterolemia An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation ", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20140313), vol. 63, no. 19, doi:10.1016/j.jacc.2014.01.063, ISSN 0735-1097, pages 1982 - 1989, XP028653361 |
| OPPOSITION | - Blacklow Stephen C, "Author manuscript: Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers", Current Opinion in Structural Biology, Elsevier Ltd., GB, GB , (20070801), vol. 17, no. 4, doi:10.1016/j.sbi.2007.08.017, ISSN 0959-440X, pages 1 - 13, XP093293057 |
| OPPOSITION | - Floren Claes-Henrik, Albers John J, Bierman Edwin L, "UPTAKE OF Lp(a) LIPOPROTEIN BY CULTURED FIBROBLASTS", Biochemical and Biophysical Research Communications, Elsevier, Amsterdam NL, Amsterdam NL , (19810930), vol. 102, no. 2, doi:10.1016/s0006-291x(81)80179-9, ISSN 0006-291X, pages 636 - 639, XP093292345 |
| OPPOSITION | - Evan A Stein, Dan Gipe, Jean Bergeron, Daniel Gaudet, Robert Weiss, Robert Dufour, Richard Wu, Robert Pordy, "Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial", The Lancet, ¬J.B. Flint|, (20120701), vol. 380, no. 9836, doi:10.1016/S0140-6736(12)60771-5, ISSN 01406736, pages 29 - 36, XP055041201 |
| OPPOSITION | - Michael J Koren, Rob Scott, Jae B Kim, Beat Knusel, Thomas Liu, Lei Lei, Michael Bolognese, Scott M Wasserman, "Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study", The Lancet, ¬J.B. Flint|, (20121201), vol. 380, no. 9858, doi:10.1016/S0140-6736(12)61771-1, ISSN 01406736, pages 1995 - 2006, XP055079129 |
| OPPOSITION | - Swergold, "REGN727/SAR236553,A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN ADMINISTERED SUBCUTANEOUSLY", ACC.11, (20110405), vol. 57, no. 14, doi:10.1016/S0735-1097(11)62023-8, XP055662879 |
| OPPOSITION | - COHEN J., ET AL., "Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Nonsense Mutations in PCSK9", Nature Genetics - Author manuscript, Nature Publishing Group US, New York, New York, (20050201), vol. 37, no. 2, doi:10.1038/ng1509, ISSN 1061-4036, pages 161 - 165, XP008102949 |
| OPPOSITION | - Lingenhel Arno, Kraft Hans Georg, Kotze Maritha, Peeters Armand V., Kronenberg Florian, Kruse Rita, Utermann Gerd, "Concentrations of the atherogenic Lp(a) are elevated in FH", European journal of human genetics, Karger, Basel, CH, CH , (19980101), vol. 6, no. 1, doi:10.1038/sj.ejhg.5200152, ISSN 1018-4813, pages 50 - 60, XP093293061 |
| OPPOSITION | - Ladenson Paul W, Jens D Kristensen, E Chester Ridgway, Anders G Olsson, Bo Carlsson, Irwin Klein, John D Baxter, Bo Angelin, "Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia", The New England Journal of medicine, (20100311), vol. 362, no. 10, doi:10.1056/NEJMoa0905633, pages 906 - 916, XP093168275 |
| OPPOSITION | - Evan A. Stein, Scott Mellis, George D. Yancopoulos, Neil Stahl, Douglas Logan, William B. Smith, Eleanor Lisbon, Maria Gutierrez, Cheryle Webb, Richard Wu, Yunling Du, Therese Kranz, Evelyn Gasparino, Gary D. Swergold, "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol", New England Journal of Medicine, New England Journal of Medicine, (20120322), vol. 366, no. 12, doi:10.1056/NEJMoa1105803, ISSN 00284793, pages 1108 - 1118, XP055049842 |
| OPPOSITION | - Stein Evan A, Scott Mellis, George D Yancopoulos, Neil Stahl, Douglas Logan, William B Smith, Eleanor Lisbon, Maria Gutierrez, Cheryle Webb, Richard Wu, Yunling Du, Therese Kranz, Evelyn Gasparino, Gary D Swergold, "Supplementary Appendix : Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol", New England Journal of Medicine, Massachusetts Medical Society, United States, United States, (20120322), vol. 366, no. 12, doi:10.1056/NEJMoa1105803, ISSN 0028-4793, pages 1 - 53, XP093292275 |
| OPPOSITION | - Eli M. Roth, James M. Mckenney, Corinne Hanotin, Gaelle Asset, Evan A. Stein, "Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia", New England Journal of Medicine, New England Journal of Medicine, (20121115), vol. 367, no. 20, doi:10.1056/NEJMoa1201832, ISSN 00284793, pages 1891 - 1900, XP055079131 |
| OPPOSITION | - CHAN JOYCE C Y ET AL, "A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (20090616), vol. 106, no. 24, doi:10.1073/pnas.0903849106, ISSN 0027-8424, pages 9820 - 9825, XP002570200 |
| OPPOSITION | - Romagnuolo Rocco, Scipione Corey A., Boffa Michael B., Marcovina Santica M., Seidah Nabil G., Koschinsky Marlys L., "Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20150501), vol. 290, no. 18, doi:10.1074/jbc.M114.611988, ISSN 0021-9258, pages 11649 - 11662, XP093193435 |
| OPPOSITION | - Børge G. Nordestgaard, M. John Chapman, Kausik Ray, Jan Borén, Felicita Andreotti, Gerald F. Watts, Henry Ginsberg, Pierre Amarenco, Alberico Catapano, Olivier S. Descamps, Edward Fisher, Petri T. Kovanen, Jan Albert Kuivenhoven, Philippe Lesnik, Luis Masana, Zeljko Reiner, Marja-Riitta Taskinen, Lale Tokgözoglu, and Anne Tybjærg-Hansen, "Lipoprotein(a) as a cardiovascular risk factor: current status", European Heart Journal, Oxford University Press, GB, GB , (20101201), vol. 31, no. 23, doi:10.1093/EURHEARTJ/EHQ386, ISSN 0195-668X, pages 2844 - 2853, XP002688211 |
| OPPOSITION | - Hobbs Helen, White Ann, "Lipoprotein (a) : Intrigues and Insights", CURRENT OPINION IN LIPIDOLOGY, Lippincott Williams and Wilkins, LONDON, GB, LONDON, GB , (19990601), vol. 10, no. 3, doi:10.1097/00041433-199906000-00005, ISSN 0957-9672, pages 225 - 236, XP009557781 |
| OPPOSITION | - Valmore Bermúdez , Arráiz Nailet, Aparicio Daniel, Rojas Edward, Gotera Daniela, Guerra Xavier, Canelón Roger, Faría Judith, Sorell Luis, Amell Anilsa, Reyna Nadia, Cabrera Mayela, Mengual Edgardo, Cano Raquel, Cano Clímaco, Velasco Manuel, "Lipoprotein(a): From Molecules to Therapeutics", AMERICAN JOURNAL OF THERAPEUTICS., Lippincott Williams & Wilkins, US, US , (20100501), vol. 17, no. 3, doi:10.1097/MJT.0b013e3181e00bf1, ISSN 1075-2765, pages 263 - 273, XP093168194 |
| OPPOSITION | - Kamstrup, P.R., "Lipoprotein(a) and ischemic heart disease-A causal association? A review", Atherosclerosis, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100701), vol. 211, no. 1, doi:10.1097/MOL.0000000000000070 , ISSN 0021-9150, pages 15 - 23, XP027353022 |
| OPPOSITION | - Lamon Fava Stefania, Diffenderfer Margaret, Marcovina Santica, "Lipoprotein(a) metabolism", CURRENT OPINION IN LIPIDOLOGY, Wolters Kluwer Lippincott Williams & Wilkins, USA, USA , (20140601), vol. 25, no. 3, doi:10.1097/MOL.0000000000000070, ISSN 1473-6535, pages 189 - 193, XP009557783 |
| OPPOSITION | - Fazio Sergio, Robertson David G., Joh Tenshang, Wan Hong, Riel Tom, Forgues Philippe, Baum Charles M., Garzone Pamela D., Gumbiner Barry, "Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin", Cardiovascular Therapeutics, (20180201), vol. 36, no. 1, doi:10.1111/1755-5922.12308, ISSN 1755-5914, pages e12308 - 9, XP093293052 |
| OPPOSITION | - Gumbiner Barry, Joh Tenshang, Liang Hong, Wan Hong, Levisetti Matteo, Vana Alicia M., Shelton David L., Forgues Philippe, Billotte Stephan, Pons Jaume, Baum Charles M., Garzone Pamela D., "‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies", Cardiovascular Therapeutics, (20180201), vol. 36, no. 1, doi:10.1111/1755-5922.12309, ISSN 1755-5914, XP093293051 |
| OPPOSITION | - Kraft H. G., Lingenhel A., Raal F. J., Hohenegger M., Utermann G, "Lipoprotein(a) in Homozygous Familial Hypercholesterolemia", Arteriosclerosis, Thrombosis, and Vascular Biology, Lippincott, Williams & Wilkins, (20240529), vol. 20, no. 2, doi:10.1161/01.ATV.20.2.522, ISSN 1079-5642, pages 522 - 528, XP093168269 |
| OPPOSITION | - Guan Weihua, Cao Jing, Steffen Brian T., Post Wendy S., Stein James H., Tattersall Mathew C., Kaufman Joel D., Mcconnell Joseph P., Hoefner Daniel M., Warnick Russell, Tsai Michael Y., "Author manuscript: Race Is a Key Variable in Assigning Lipoprotein(a) Cutoff Values for Coronary Heart Disease Risk Assessment : The Multi-Ethnic Study of Atherosclerosis", Arteriosclerosis, Thrombosis, and Vascular Biology, Lippincott, Williams & Wilkins, (20150401), vol. 35, no. 4, doi:10.1161/ATVBAHA.114.304785, ISSN 1079-5642, pages 1 - 14, XP093293065 |
| OPPOSITION | - F. Raal, R. Scott, R. Somaratne, I. Bridges, G. Li, S. M. Wasserman, E. A. Stein, "Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial", Circulation, American Heart Association, US, US , (20121113), vol. 126, no. 20, doi:10.1161/CIRCULATIONAHA.112.144055, ISSN 0009-7322, pages 2408 - 2417, XP055139587 |
| OPPOSITION | - Desai Nihar R., Kohli Payal, Giugliano Robert P., O’donoghue Michelle L., Somaratne Ransi, Zhou Jing, Hoffman Elaine B., Huang Fannie, Rogers William J., Wasserman Scott M., Scott Robert, Sabatine Marc S., "AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy : An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial", Circulation, American Heart Association, US, US , (20130827), vol. 128, no. 9, doi:10.1161/CIRCULATIONAHA.113.001969, ISSN 0009-7322, pages 962 - 969, XP093293050 |
| OPPOSITION | - Krempler Franz, Kostner Gerhard M., Bolzano Klaus, Sandhofer Friedrich, "Turnover of Lipoprotein (a) in Man", Journal of Clinical Investigation, American Society for Clinical Investigation, (19800601), vol. 65, no. 6, doi:10.1172/JCI109813, ISSN 0021-9738, pages 1483 - 1490, XP093293054 |
| OPPOSITION | - Krempler F, Kostner G M, Roscher A, Haslauer F, Bolzano K, Sandhofer F, "Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man.", Journal of Clinical Investigation, American Society for Clinical Investigation, (19830501), vol. 71, no. 5, doi:10.1172/JCI110896, ISSN 0021-9738, pages 1431 - 1441, XP093168203 |
| OPPOSITION | - Hofmann S L, Eaton D L, Brown M S, Mcconathy W J, Goldstein J L, Hammer R E, "Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice.", Journal of Clinical Investigation, American Society for Clinical Investigation, (19900501), vol. 85, no. 5, doi:10.1172/JCI114602, ISSN 0021-9738, pages 1542 - 1547, XP093168217 |
| OPPOSITION | - Rader D J, Cain W, Ikewaki K, Talley G, Zech L A, Usher D, Brewer H B, "The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.", Journal of Clinical Investigation, American Society for Clinical Investigation, (19940601), vol. 93, no. 6, doi:10.1172/JCI117292, ISSN 0021-9738, pages 2758 - 2763, XP093293055 |
| OPPOSITION | - D J Rader, W A Mann, W Cain, H G Kraft, D Usher, L A Zech, J M Hoeg, J Davignon, P Lupien, M Grossman, "The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.", Journal of Clinical Investigation, (19950301), vol. 95, no. 3, doi:10.1172/JCI117794, ISSN 00219738, pages 1403 - 1408, XP055215915 |
| OPPOSITION | - Yan G. Ni, Stefania Di Marco, Jon H. Condra, Laurence B. Peterson, Weirong Wang, Fubao Wang, Shilpa Pandit, Holly A. Hammond, Ray Rosa, Richard T. Cummings, Dana D. Wood, Xiaomei Liu, Matthew J. Bottomley, Xun Shen, Rose M. Cubbon, Sheng-ping Wang, Douglas G. Johns, Cinzia Volpari, Lora Hamuro, Jayne Chin, Lingyi Huang, Jing Zhang Zhao, Salvatore Vitelli, Peter Haytko, Douglas Wisniewski, Lyndon J. Mitnaul, Carl P. Sparrow, Brian Hubbard, Andrea Carfí, and Ayesha Sitlani, "A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo", JOURNAL OF LIPID RESEARCH, American Society for Biochemistry and Molecular Biology, Inc., US, US , (20110101), vol. 52, no. 1, doi:10.1194/jlr.m011445, ISSN 0022-2275, pages 78 - 86, XP002686538 |
| OPPOSITION | - Ober Carole, Nord Alex S., Thompson Emma E., Pan Lin, Tan Zheng, Cusanovich Darren, Sun Ying, Nicolae Raluca, Edelstein Celina, Schneider Daniel H., Billstrand Christine, Pfaffinger Ditta, Phillips Natasha, Anderson Rebecca L., Philips Binu, Rajagopalan Ramakrishnan, Hatsukami Thomas S., Rieder Mark J., Heagerty Patrick J., Nickerson Deborah A., Abney Mark, Marcovina Santica, Jarvik Gail P., Scanu Angelo M., Nicolae Dan L., "Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q", JOURNAL OF LIPID RESEARCH, American Society for Biochemistry and Molecular Biology, Inc., US, US , (20090501), vol. 50, no. 5, doi:10.1194/jlr.M800515-JLR200, ISSN 0022-2275, pages 798 - 806, XP093193431 |
| OPPOSITION | - Frederick J. Raal, Robert P. Giugliano, Marc S. Sabatine, Michael J. Koren, Dirk Blom, Nabil G. Seidah, Narimon Honarpour, Armando Lira, Allen Xue, Padmaja Chiruvolu, Simon Jackson, Mei Di, Matthew Peach, Ransi Somaratne, Scott M. Wasserman, Rob Scott, Evan A. Stein, "PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role", JOURNAL OF LIPID RESEARCH, American Society for Biochemistry and Molecular Biology, Inc., US, US , (20160601), vol. 57, no. 6, doi:10.1194/jlr.P065334, ISSN 0022-2275, pages 1086 - 1096, XP055690739 |
| OPPOSITION | - Konrad Schmidt, Asma Noureen, Florian Kronenberg, Gerd Utermann, "Structure, function, and genetics of lipoprotein (a)", JOURNAL OF LIPID RESEARCH, American Society for Biochemistry and Molecular Biology, Inc., US, US , (20160801), vol. 57, no. 8, doi:10.1194/jlr.R067314, ISSN 0022-2275, pages 1339 - 1359, XP055502476 |
| OPPOSITION | - Kostner Karam M., Kostner Gert M., "Lipoprotein (a): a historical appraisal", JOURNAL OF LIPID RESEARCH, American Society for Biochemistry and Molecular Biology, Inc., US, US , (20170101), vol. 58, no. 1, doi:10.1194/jlr.R071571, ISSN 0022-2275, pages 1 - 14, XP093293059 |
| OPPOSITION | - Hiroki Ikenaga, Masaharu Ishihara, Ichiro Inoue, Takuji Kawagoe, Yuji Shimatani, Fumiharu Miura, Yasuharu Nakama, Kazuoki Dai, Takayuki Otani, Kentaro Ejiri, Nozomu Oda, Masayuki Nakamura, Takashi Miki, "Usefulness of Lipoprotein (a) for Predicting Progression of Non-Culprit Coronary Lesions After Acute Myocardial Infarction", CIRCULATION JOURNAL, JAPANESE CIRCULATION SOCIETY, KYOTO, JP, JP , (20110101), vol. 75, no. 12, doi:10.1253/circj.CJ-11-0365, ISSN 1346-9843, pages 2847 - 2852, XP055540050 |
| OPPOSITION | - Mora Samia, Kamstrup Pia R, Rifai Nader, Nordestgaard Børge G, Buring Julie E, Ridker Paul M, "Author Manuscript : Lipoprotein(a) and Risk of Type 2 Diabetes", Clinical Chemistry, Oxford University Press, US, US , (20100801), vol. 56, no. 8, doi:10.1373/clinchem.2010.146779, ISSN 0009-9147, pages 1 - 15, XP093292343 |
| OPPOSITION | - PARHOFER KLAUS G, "Lipoprotein(a): Medical Treatment Options for an Elusive Molecule", Current Pharmaceutical Design, Bentham Science Publishers, NL, NL , (20110301), vol. 17, no. 9, doi:10.2174/138161211795428777, ISSN 1381-6128, pages 871 - 876, XP002688212 |
| OPPOSITION | - Ioanna Gouni-Berthold, Heiner K. Berthold, "Lipoprotein(a): Current Perspectives", CURRENT VASCULAR PHARMACOLOGY, BENTHAM SCIENCE PUBLISHER, HILVERSUM, NL, NL , (20111101), vol. 9, no. 6, doi:10.2174/157016111797484071, ISSN 1570-1611, pages 682 - 692, XP055497835 |
| OPPOSITION | - Sechi Leonardo, Zingaro Laura, De Carli Stefano, Sechi Giovanni, Catena Cristiana, Falleti Edmondo, Dell'anna Elisabetta, Bartoli Ettore, "Increased Serum Lipoprotein(a) Levels in Patients with Early Renal Failure", Annals of Internal Medicine, Philadelphia, Pa. : American College of Physicians, 1927, US, US , (19980915), vol. 129, no. 6, doi:10.7326/0003-4819-129-6-199809150-00006 , ISSN 1539-3704, pages 457 - 461, XP009561817 |
| SEARCH | - NORDESTGAARD BORGE G ET AL, "Lipoprotein(a) as a cardiovascular risk factor: current status", EUROPEAN HEART JOURNAL, (201012), vol. 31, no. 23, ISSN 0195-668X, page 2844, XP002688211 [A] 1-15 * abstract * |
| SEARCH | - PARHOFER KLAUS G, "Lipoprotein(a): Medical Treatment Options for an Elusive Molecule", CURRENT PHARMACEUTICAL DESIGN, (201103), vol. 17, no. 9, ISSN 1381-6128, pages 871 - 876, XP002688212 [Y] 1-15 * table 3 * |
